Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, Iivanainen S, Shetty S, Ma YT, Graham DM, Arora SP, Jaakkola P, Yap C, Xiang Y, Mandelin J, Karvonen MK, Jalkanen J, Karaman S, Koivunen JP, Minchom A, Hollmén M, Bono P.
Rannikko JH, et al.
Cell Rep Med. 2023 Dec 19;4(12):101307. doi: 10.1016/j.xcrm.2023.101307. Epub 2023 Dec 5.
Cell Rep Med. 2023.
PMID: 38056464
Free PMC article.
Clinical Trial.
Macrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-tumor immunity. ...DC associates with improved survival in a landmark analysis and correlates with high pre-treatment intratumoral Clever-1 positivity and increasing on-treatmen …
Macrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-tumor immunity. ...DC associates with improv …